Search

Your search keyword '"Hero, B."' showing total 13 results

Search Constraints

Start Over You searched for: Author "Hero, B." Remove constraint Author: "Hero, B." Topic biomarkers, tumor Remove constraint Topic: biomarkers, tumor
13 results on '"Hero, B."'

Search Results

1. Biochemical testing for neuroblastoma using plasma free 3-O-methyldopa, 3-methoxytyramine, and normetanephrine.

2. Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence.

3. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.

4. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.

5. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.

6. Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease.

7. Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification.

8. Lacking immunocytological GD2 expression in neuroblastoma: report of 3 cases.

9. Tumour markers are poor predictors for relapse or progression in neuroblastoma.

10. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.

11. Traditional and emerging molecular markers in neuroblastoma prognosis: the good, the bad and the ugly.

12. Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma.

13. The current contribution of molecular factors to risk estimation in neuroblastoma patients.

Catalog

Books, media, physical & digital resources